ATE175676T1 - Propiophenon-derivate und verfahren zur ihrer herstellung - Google Patents

Propiophenon-derivate und verfahren zur ihrer herstellung

Info

Publication number
ATE175676T1
ATE175676T1 AT96117088T AT96117088T ATE175676T1 AT E175676 T1 ATE175676 T1 AT E175676T1 AT 96117088 T AT96117088 T AT 96117088T AT 96117088 T AT96117088 T AT 96117088T AT E175676 T1 ATE175676 T1 AT E175676T1
Authority
AT
Austria
Prior art keywords
production
hydrogen atom
propiophenone derivatives
propiophenone
derivatives
Prior art date
Application number
AT96117088T
Other languages
English (en)
Inventor
Kenji Tsujihara
Kunio Saito
Mitsuya Hongu
Mamoru Matsumoto
Kozo Doeru Shugakuin Oka
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of ATE175676T1 publication Critical patent/ATE175676T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT96117088T 1995-11-07 1996-10-24 Propiophenon-derivate und verfahren zur ihrer herstellung ATE175676T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7288487A JP3059088B2 (ja) 1995-11-07 1995-11-07 プロピオフェノン誘導体およびその製法

Publications (1)

Publication Number Publication Date
ATE175676T1 true ATE175676T1 (de) 1999-01-15

Family

ID=17730854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96117088T ATE175676T1 (de) 1995-11-07 1996-10-24 Propiophenon-derivate und verfahren zur ihrer herstellung

Country Status (12)

Country Link
US (1) US5767094A (de)
EP (1) EP0773226B1 (de)
JP (1) JP3059088B2 (de)
KR (1) KR100333572B1 (de)
CN (1) CN1049222C (de)
AT (1) ATE175676T1 (de)
CA (1) CA2189603C (de)
DE (1) DE69601345T2 (de)
DK (1) DK0773226T3 (de)
ES (1) ES2128137T3 (de)
SG (1) SG40895A1 (de)
TW (1) TW460477B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216704T1 (de) * 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
AU5755200A (en) 1999-08-27 2001-03-26 Joel R.L. Ehrenkranz Method of using dihydrochalcone derivatives to block glucose transfer
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2442917C (en) * 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
EP1392326B1 (de) * 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CA2549015A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
EA011515B1 (ru) * 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EP1680131A4 (de) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv Substituierte indol-o-glucoside
ES2649737T5 (es) * 2003-08-01 2021-07-07 Mitsubishi Tanabe Pharma Corp Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
RS20060320A (sr) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
FR2862303B1 (fr) * 2003-11-17 2006-01-06 Agronomique Inst Nat Rech Preparations colorantes hydrosolubles jaunes derivees des dihydrochalcones, leur procede des preparation, et leurs utilisations
TWI332707B (en) 2005-08-04 2010-11-01 Au Optronics Corp Array substrate of a liquid crystal display and method of fabricating the same
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
UA105480C2 (uk) * 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
LT2488515T (lt) * 2009-10-14 2017-03-10 Janssen Pharmaceutica Nv Junginių, naudotinų kaip sglt2 inhibitorių, paruošimo būdas
EP2568988B1 (de) 2010-05-11 2016-07-13 Janssen Pharmaceutica, N.V. Pharmazeutische zubereitungen enthaltend 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzol derivate mit sglt inhibitorischer wirkung
JP5973551B2 (ja) 2011-04-13 2016-08-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｓｇｌｔ２の阻害物質として有用な化合物の調製プロセス
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CA3116533A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
EP4469038A1 (de) 2022-01-26 2024-12-04 Astrazeneca AB Dapagliflozin zur verwendung bei der behandlung von prädiabetes oder zur verringerung des risikos der entwicklung von diabetes typ 2
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760135A (en) * 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same

Also Published As

Publication number Publication date
ES2128137T3 (es) 1999-05-01
KR100333572B1 (ko) 2002-09-18
CA2189603A1 (en) 1997-05-08
DK0773226T3 (da) 1999-08-30
KR970027098A (ko) 1997-06-24
DE69601345T2 (de) 1999-06-17
JP3059088B2 (ja) 2000-07-04
MX9605415A (es) 1997-10-31
CN1049222C (zh) 2000-02-09
CN1151405A (zh) 1997-06-11
SG40895A1 (en) 1997-06-14
EP0773226B1 (de) 1999-01-13
JPH09124686A (ja) 1997-05-13
CA2189603C (en) 2003-06-10
EP0773226A1 (de) 1997-05-14
US5767094A (en) 1998-06-16
DE69601345D1 (de) 1999-02-25
TW460477B (en) 2001-10-21

Similar Documents

Publication Publication Date Title
ATE175676T1 (de) Propiophenon-derivate und verfahren zur ihrer herstellung
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
HU9600834D0 (en) Quinazoline derivatives
AU5752194A (en) Benzimidazole compounds, their use and preparation
DE69817802D1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
ATE178069T1 (de) Propiophenonderivate und verfahren zu deren herstellung
MY119350A (en) Propiophenone derivatives and process for preparing the same
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
DE3767672D1 (de) Chinazolinonderivat und verfahren zu seiner herstellung.
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
ATE207749T1 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung von atherosklerose und ischämischer herzerkrankungen
ATE246180T1 (de) Benzofuranon-derivate und verfahren zu ihrer herstellung
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
AU3797189A (en) Piperidine derivatives
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
EP0342587A3 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung
EP1034783A4 (de) Amidederivaten
HUT50354A (en) Process for producing new s-adenosylmethionine decarboxilase inhibitors
AU2002214325A1 (en) Process for producing carbapenem-type antibacterial
CA2089207A1 (en) Amphoteric Tricyclic Compound
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
EP0794184A4 (de) 6-methoxy-1h-benzotriazol-5-carboxamide-derivate, verfahren zur herstellung und diese enthaltende arzneimittel
EP0784973A3 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE3767533D1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification